全文获取类型
收费全文 | 539篇 |
免费 | 15篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 21篇 |
妇产科学 | 5篇 |
基础医学 | 44篇 |
口腔科学 | 6篇 |
临床医学 | 19篇 |
内科学 | 103篇 |
皮肤病学 | 63篇 |
神经病学 | 6篇 |
特种医学 | 24篇 |
外科学 | 22篇 |
综合类 | 2篇 |
预防医学 | 7篇 |
眼科学 | 3篇 |
药学 | 15篇 |
中国医学 | 2篇 |
肿瘤学 | 203篇 |
出版年
2022年 | 2篇 |
2021年 | 6篇 |
2020年 | 5篇 |
2019年 | 12篇 |
2018年 | 9篇 |
2017年 | 3篇 |
2016年 | 6篇 |
2015年 | 7篇 |
2014年 | 10篇 |
2013年 | 8篇 |
2012年 | 21篇 |
2011年 | 25篇 |
2010年 | 14篇 |
2009年 | 24篇 |
2008年 | 28篇 |
2007年 | 21篇 |
2006年 | 16篇 |
2005年 | 15篇 |
2004年 | 16篇 |
2003年 | 14篇 |
2002年 | 24篇 |
2001年 | 28篇 |
2000年 | 17篇 |
1999年 | 20篇 |
1998年 | 17篇 |
1997年 | 14篇 |
1996年 | 15篇 |
1995年 | 13篇 |
1994年 | 10篇 |
1993年 | 14篇 |
1992年 | 12篇 |
1991年 | 6篇 |
1990年 | 10篇 |
1989年 | 10篇 |
1988年 | 16篇 |
1987年 | 12篇 |
1986年 | 7篇 |
1985年 | 8篇 |
1984年 | 8篇 |
1983年 | 8篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1979年 | 4篇 |
1978年 | 7篇 |
1977年 | 3篇 |
1975年 | 5篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1941年 | 1篇 |
排序方式: 共有561条查询结果,搜索用时 0 毫秒
31.
BACKGROUND: The authors previously reported that central lymphatic irradiation (CLI) can induce molecular remission in patients with Stage I-III follicular lymphoma, as measured by polymerase chain reaction analysis for t(14;18) (q32;q21). Hematologic toxicity has been considered a major consequence of CLI. This study was undertaken to analyze the patterns of hematologic recovery after CLI. METHODS: Thirty-three patients with Stage I-III follicular lymphoma were treated with CLI between January 1993 and February 1998. CLI consisted of irradiation to mantle, upper two-thirds of abdomen, and pelvic fields. Each field was treated to 30.0-30.6 grays (Gy) at 1.5-1.8 Gy per fraction, with a boost to 36.0-39.6 Gy at the same rate to the sites of macroscopic disease. A break of approximately 4 weeks was given after treatment of each field. Twenty-four patients who were followed for a minimum of 1 year from the end of CLI form the basis of this analysis. Fourteen patients were male. Three patients had Stage I disease, 6 patients had Stage II disease, and 15 patients had Stage III disease. The International Prognostic Index (IPI) for malignant lymphoma was 0 for 5 patients, 1 for 13 patients, and 2 for 6 patients. The Eastern Cooperative Oncology Group performance status was 0 for 21 patients and 1 for 3 patients. The median values for their pretreatment characteristics were as follows: age, 60 years (range, 34-73 years); height, 173 cm (range, 155-193 cm); weight, 79 kg (range, 57-107 kg); body surface area (BSA), 1.95 m(2) (range, 1.61-2.31 m(2)); bone marrow cellularity, 27%(range, 2-75%), platelet count, 233,000/mm(3) (range, 139,000-339,000/mm(3)), white blood cell (WBC) counts, 6400/mm(3) (range, 4200-10,900/mm(3)); and hemoglobin, 14.5 mg/dL (range, 11.8 -16.6 mg/dL). The median duration of CLI was 159 days (range, 137-345 days). Ten patients had cardiovascular disease. The number of sites receiving a boost dose of > or = 36.0 Gy was 0 sites in 1 patient, 1 site in 6 patients, 2 sites in 11 patients, 3 sites in 5 patients, and 4 sites in 1 patient. The platelet, hemoglobin, and WBC counts were followed every 3 months after completion of CLI. These counts were normalized to the pretreatment counts for statistical analyses. Univariate and multivariate analyses were performed to investigate the correlations between patient factors and hematologic status at 1 year posttreatment. Pearson correlation analysis was used for the continuous factors (patient age, height, weight, BSA, bone marrow cellularity, and duration of CLI), and the Mann-Whitney test was used for categoric factors (IPI, gender, performance status, stage, number of sites receiving > or = 36.0 Gy, and presence or absence of cardiovascular disease). RESULTS: There was continued recovery, essentially approaching the pretreatment levels, over 3 years for platelet, WBC, and hemoglobin counts. Factors that were associated significantly with normalized platelet counts at 1 year by univariate analyses were age (P = 0.015) and cardiovascular disease (P = 0.041). Age was the only significant factor by multivariate analyses, with older patients having lower platelet counts at 1 year posttreatment. No factors were found that were associated significantly with 1-year normalized WBC or hemoglobin levels by either univariate or multivariate analyses. CONCLUSIONS: All three of the hematologic components (platelets, WBC, and hemoglobin) essentially recover after patients undergo CLI over a 3-year period. Older age was the only significant adverse factor that affected the platelet recovery, as detected by multivariate analysis. (c) 2001 American Cancer Society. 相似文献
32.
Page RD Romaguera JE Osborne B Medeiros LJ Rodriguez J North L Sanz-Rodriguez C Cabanillas F 《Cancer》2001,92(8):2023-2029
BACKGROUND: Primary hepatic non-Hodgkin lymphoma (PHL) is a rare and difficult to diagnose lymphoproliferative disorder of unknown etiology. It is believed that the prognosis in affected patients is dismal, consisting of early recurrence and short survival. METHODS: A retrospective cohort review of patients with PHL diagnosed between 1974 and 1995 at a university cancer center was performed. RESULTS: Twenty-four patients with PHL were identified. Typically, the disease occurred in middle-aged men (median age, 50 years). The primary presenting complaint was right upper quadrant abdominal pain, with hepatomegaly found at physical examination. Serum liver enzymes, lactate dehydrogenase, and beta-2-microglobulin levels all were elevated, but alpha-fetoprotein and carcinoembryonic antigen levels were within normal range. Hypercalcemia was found in 6 of 15 patients who were tested. Six of 10 patients who were tested were positive for the hepatitis C virus (HCV). Liver scans demonstrated either a solitary lesion or multiple lesions. Pathologic examination revealed diffuse large cell lymphoma in 23 patients (96%). Combination chemotherapy was the mainstay of treatment; surgery consisted of diagnostic biopsy. The complete remission rate was 83.3%, and the 5-year cause specific and failure free survival rates were 87.1% and 70.1%, respectively. HCV infection did not appear to influence the outcome of therapy. CONCLUSIONS: The outcome of patients with PHL who are treated with combination chemotherapy may be more favorable than that reported elsewhere. The frequent association of PHL with HCV infection observed in this series warrants further investigation. 相似文献
33.
Umut Disel Russell Madison Kumar Abhishek Jon H. Chung Sally E. Trabucco Asli O. Matos Garrett M. Frampton Lee A. Albacker Venkataprasanth Reddy Nuri Karadurmus Adam Benson Jennifer Webster Semra Paydas Ruben Cabanillas Chaitali Nangia M.A. Ozturk Sherri Z. Millis Sumanta K. Pal Breelyn Wilky Ethan S. Sokol Laurie M. Gay Salil Soman Shridar Ganesan Katherine Janeway Phil J. Stephens Viola W. Zhu Sai-Hong Ignatius Ou Christine M. Lovly Mrinal Gounder Alexa B. Schrock Jeffrey S. Ross Vincent A. Miller Samuel J. Klempner Siraj M. Ali 《The oncologist》2020,25(1):e39-e47
34.
The clinical relevance of t(14; 18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma 总被引:1,自引:0,他引:1
Background: t(14; 18)/bcl-2 gene rearrangement (R) is claimedto impart a worse rate of complete remission and disease-freesurvival in diffuse large cell lymphoma (DLCL). DEL 6q has alsobeen associated with poor outcome. Design: Retrospective studyof 54 patients with either diffuse large cell or immunoblasticlymphoma who had cytogenetics and/or molecular studies performed.Results: Patient characteristics, complete remission rate, andtime to treatment failure (TTF) were similar at three year follow-upfor groups with and without t(14; 18)/BCL-2R Survival was worsefor the former but the difference was not statistically significant.For DEL 6q, patient characteristics and survival rates weresimilar at three year follow-up for patients with and withoutthe abnormality. TTF was worse for the former but this was notstatistically significant. Conclusion: This study, with equalor greater number of patients with t(14; 18) than previous reports,fails to show a worse prognosis for patients with the t(14;18) chromosomal abnormality. A definite association will awaitfurther accrual of patients and a meaningul multivariate analysis. lymphoma, BCL-2, cytogenetics, DEL 6q 相似文献
35.
36.
R Luthra A H Sarris S Hai A V Paladugu J E Romaguera F F Cabanillas L J Medeiros 《American journal of clinical pathology》1999,112(4):524-530
We describe the usefulness of a real-time polymerase chain reaction (PCR) assay for detection of the t(11;14)(q13;q32), most commonly present in mantle cell lymphoma (MCL). This assay is based on the 5'-->3' exonuclease activity of Taq polymerase, which cleaves an internal probe labeled with a reporter dye at its 5' end and a quencher dye at its 3' end during PCR. The real-time t(11;14) PCR assay was established using DNA from a case of MCL with the t(11;14), amplifiable using conventional PCR and primers specific for the major translocation cluster (MTC) region of the bcl-1 locus and the immunoglobulin heavy chain joining region gene (JH). The specificity was determined by analyzing DNA from 82 cases: 50 MCL, 27 other types of non-Hodgkin lymphoma (NHL), and 5 reactive lymphoid proliferations. The real-time t(11;14) PCR results were correlated with data obtained by a conventional PCR assay. By using the real-time assay, bcl-1 MTC/JH DNA fusion sequences were detected in 25 of 50 MCLs but not in other NHLs or reactive lymphoid proliferations. Concordance between real-time and conventional PCR methods for MCL was 96% and for all samples was 98%. The results demonstrate that this real-time PCR method to detect bcl-1 MTC/JH DNA fusion sequences is specific and reliable. In addition, the results are available immediately following amplification, without standard post-PCR manipulations. 相似文献
37.
Casanueva FF Molitch ME Schlechte JA Abs R Bonert V Bronstein MD Brue T Cappabianca P Colao A Fahlbusch R Fideleff H Hadani M Kelly P Kleinberg D Laws ED Marek J Scanlon M Sobrinho LG Wass JAH Giustina A 吴哲褒 张亚卓 《中华神经外科杂志》2008,24(8)
3.男性:高催乳素血症通常导致阳痿、不孕和性功能低下.男性患者通常为大腺瘤,有神经系统症状.其原因可能是对症状认识的延误或者肿瘤生物学行为的差异. 相似文献
38.
Fine needle aspiration diagnosis of intraabdominal and retroperitoneal lymphomas by a morphologic and immunocytochemical approach 总被引:4,自引:0,他引:4
We reviewed 238 fine needle aspiration biopsies (FNA) of intraabdominal or retroperitoneal (IA/RP) masses in 192 patients with known or suspected lymphoma. A limited battery of immunocytochemical stains, including kappa (k) and lambda (l) light chains and Leu-4, was performed in 104 aspirates. On hundred twenty-eight of the FNA were diagnostic of or consistent with lymphoma, and three were diagnostic of carcinoma. Twenty-eight were considered negative for malignancy and 79 were suspicious for lymphoma or were nondiagnostic. For 135 of the FNA, a histologic biopsy specimen was available for comparison purposes. Overall, only one false-positive result was seen in a specimen lacking immunocytochemical data. The sensitivity of FNA lymphoma diagnosis was 66%. False-negative results due to sampling error were not uncommon, giving a predictive value of a negative result as 42%. The classification of the lymphomas by FNA was identical to that of the surgical biopsy in 86% of specimens and concurrently discrepant in 6%. We conclude that the routine performance of immunocytochemical studies on FNA of IA/RP masses is a feasible and valuable technique. Whereas suboptimal sensitivity and sampling error may make a negative diagnosis unreliable, lymphoma marker studies (combined with morphology) allow for an accurate and confident diagnosis and subclassification of lymphoma in the majority of cases. 相似文献
39.
40.
Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer 下载免费PDF全文
Israel Pena MD Gary L. Clayman MD Elizabeth G. Grubbs MD Jeffrey M. Bergeron BS Jr Steven G. Waguespack MD Maria E. Cabanillas MD Ramona Dadu MD Mimi I. Hu MD Bryan M. Fellman MS Yisheng Li PhD Neil D. Gross MD Stephen Y. Lai MD PhD Erich M. Sturgis MD Mark E. Zafereo MD 《Head & neck》2018,40(1):79-85